Friday November 27 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioPortfolio's Approved Drugs Database

Valcyte

Valganciclovir Hydrochloride

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Press Releases About Valcyte:

 BioPortfolio Logo
IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant 1st June, 2009 Roche Pharmaceuticals
CMV is the most serious viral infection affecting transplant patients BOSTON, June 1 /PRNewswire/ -- New Phase III study results presented for the first time today at the ninth annual American

This page has been viewed 28 times Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Valcyte across BioPortfolio, or for Valcyte Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.